(Q51222196)

English

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

scientific article published on 23 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. (English)

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

Barjesh Chander Sharma

1

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

Praveen Sharma

2

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

Manish Kumar Lunia

3

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

Siddharth Srivastava

4

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

Rohit Goyal

5

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

S K Sarin

6

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

language of work or name

0 references

publication date

23 July 2013

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

108

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

9

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

1458-1463

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Review article: the burden of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin treatment in hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin for the treatment of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin for treatment of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Rifaximin pharmacology and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.219

21 January 2018

Identifiers

10.1038/AJG.2013.219

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/23877348

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51222196&oldid=1575905122"